Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Risico op renale bijwerkingen van TDF-gebaseerde PrEP
mrt 2022 | HIV, Virale infecties